Scarica l'app Stockscreener
5.72
2.05%
-0.12
Pre-mercato:
5.59
-0.13
-2.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$5.84
Aprire:
$5.87
Volume 24 ore:
10.58M
Relative Volume:
0.44
Capitalizzazione di mercato:
$2.26B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.6903
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+1.60%
1M Prestazione:
-1.55%
6M Prestazione:
-15.13%
1 anno Prestazione:
-30.24%
Intervallo 1D:
$5.68
$5.94
Intervallo di 1 settimana:
$5.54
$6.11
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.72 | 2.26B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - Bluefield Daily Telegraph
TechBio Pioneer Recursion Announces Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
Why Biohaven Stock Plummeted by More Than 15% Today - The Motley Fool
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Recursion (RXRX) to Reveal Promising Data on REC-4881 for FAP Tr - GuruFocus
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know - MSN
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - marketscreener.com
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - marketscreener.com
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - Yahoo Finance
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? - MSN
Recursion Pharma (RXRX) Stock Climbs Amid FDA Shift In Testing R - GuruFocus
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today - MSN
Biotech Revolution: FDA’s New Era Signals Dramatic Shift in Drug Development - macnifico.pt
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? - The Globe and Mail
Recursion Pharma rises, Intel & Five Below fall: Trending Tickers - Yahoo Finance
Recursion: FDA To Replace Animal Testing With AI?A Small But Necessary Win - Seeking Alpha
Recursion (RXRX) Utilizes AI for Enhanced Drug Discovery - GuruFocus
The AI Revolution in Biotech: Recursion Pharmaceuticals Soars 19.18% on FDA's New Approach to Animal Testing - RagingBull
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? - Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated - MSN
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study - Zacks Investment Research
Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform - TipRanks
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):